Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of $0.02 per share. This is a 102.02 percent increase over losses of $(0.99) per share from the same period last year.
Traders Circulate Post Suggesting Novartis AG ‘Misses On 2nd Interim For NATALEE Trial. Not A Good Sign For Differentiation Vs Abema’
https://twitter.com/pharmacreep/status/1612487217800167424